Evidence map›Paper›PMID 40161652›Full record

ArticlebioRxiv : the preprint server for biology2025

Unpacking bedaquiline hetero-resistance: the importance of intermediate profiles for phenotypic drug-susceptibility testing.

Nabila Ismail, Frik Sirgel, Shaheed Vally Omar, Shatha Omar, Marianna de Kock, Claudia Spies, Megan Folkerts, Grant Theron, Dave Engelthaler, John Metcalfe and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Nabila IsmailSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Frik SirgelSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Shaheed Vally OmarCentre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg, South Africa.ORCID 0000-0003-0734-7149
Shatha OmarSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Marianna de KockSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Claudia SpiesSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Megan FolkertsTranslational Genomics Research Institute (TGen) North Clinical Laboratory, Flagstaff, Arizona, United States of America.
Grant TheronSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-2877-2419
Dave EngelthalerTranslational Genomics Research Institute (TGen) North Clinical Laboratory, Flagstaff, Arizona, United States of America.ORCID 0000-0001-5945-059X
John MetcalfeUniversity of California-San Francisco, San Francisco, California, United States of America.
Robin M WarrenSouth African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Funding

The Center for Innovation in Point-of-Care Technologies for HIV/AIDS atNorthwestern University (C-THAN) Supplemental RequestU54EB027049 · NIBIB · NORTHWESTERN UNIVERSITY · PI Chad J Achenbach · 2018 to 2026
$24.0M
Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)U01AI152087 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CATTAMANCHI, ADITHYA, DENKINGER, CLAUDIA MARIA · 2020 to 2024
$19.3M
Novel next-generation sequencing assay for monitoring multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI131939 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ENGELTHALER, DAVID M, METCALFE, JOHN ZAPATA · 2018 to 2023
$3.9M
HIV and Mycobacterial Disease in MaliD43TW010350 · FIC · UNIV OF SCIENCES, TECH & TECH OF BAMAKO · PI MAIGA, ALMOUSTAPHA ISSIAKA, MURPHY, ROBERT LEO · 2016 to 2025
$3.0M
Pre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosisR01AI136894 · NIAID · STELLENBOSCH UNIVERSITY · PI THERON, GRANT DE VOS · 2019 to 2023
$678k
FIC NIH HHS D43 TW010350NIAID NIH HHS R01 AI131939NIAID NIH HHS R01 AI136894NIAID NIH HHS U01 AI152087NIBIB NIH HHS U54 EB027049
6 · The paper itself

Abstract

Phenotypic drug susceptibility testing (pDST) remains the gold standard for

Indexed as

bedaquilineheteroresistanceMycobacterium tuberculosisphenotypic susceptibility testing

Identifiers

PMID40161652
PMCPMC11952369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.